Top 5 Stock Upgrades Today: Analysts Signal Big Upside Ahead

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  08 Aug 2025
 

•   ANET  
   
  -0.52%
•   APP  
   
  +1.50%

$GILD Gilead Sciences earned a major analyst upgrade from Needham, shifting from Hold to Buy with a new $133 price target. The bullish call is fueled by optimism ahead of the company’s upcoming earnings and steady revenue outlook. Beyond the fundamentals, Gilead’s strong dividend yield and renewed interest in its HIV and oncology pipelines are reinforcing investor confidence. As analysts shift their tone, GILD is emerging as one of the most compelling large-cap biotech opportunities on the market.

$APP AppLovin continues to gain bullish momentum following several analyst upgrades from Bank of America, JPMorgan, Goldman Sachs, and Loop Capital. The core theme? AppLovin is proving it can expand beyond gaming into broader advertising and eCommerce success. Analysts note that Q3 might be softer, but the long-term growth story remains intact, especially heading into FY2026. With a track record of execution and strong demand signals, APP is turning heads across Wall Street.

$MTG MGIC Investment received a meaningful boost as Moody’s upgraded both its senior unsecured debt rating and the insurance financial strength of its main operating entity. The move reflects growing confidence in the company's risk profile and financial health. As the mortgage insurance space remains resilient, MGIC is now seen as a more stable, attractive option for value-focused investors seeking strong fundamentals with improving credit quality.

$ELTX Elicio Therapeutics is drawing fresh interest after the Independent Data Monitoring Committee gave the green light to continue its Phase 2 trial in pancreatic cancer. The decision reflects promising interim data without safety concerns, reinforcing optimism around its lead immunotherapy candidate. With biotech investors hunting for high-reward clinical-stage opportunities, ELTX is quietly positioning itself as one to watch in the oncology space.

$ANET Arista Networks was upgraded on the back of exceptional earnings and rising demand in AI infrastructure and cloud data centers. Analysts see long-term upside as the company continues to benefit from secular trends driving networking expansion. Arista's strong operational performance, product leadership, and customer adoption are giving investors a renewed reason to lean in, particularly as enterprise and hyperscale markets accelerate.